Classifieds - Imaging in Oncology
Taking place in London this year, SMi’s Imaging in Oncology will focus on a wide range of imaging techniques in a wide range of settings - from the preclinical, to the clinical, to the future of oncological imaging.
Imaging in Oncology10th and 11th March 2010, Crowne Plaza St James Hotel, London
Sponsored by:Bioclinica, Bracco, Caliper Lifesciences, Perceptive Informatics and Rad Pharm
For more information visit us at: www.smi-online.co.uk/2010oncology24.asp
Taking place in London this year, SMi’s Imaging in Oncology will focus on a wide range of imaging techniques in a wide range of settings - from the preclinical, to the clinical, to the future of oncological imaging.
Attend this event to
• Hear from the leading lights of the imaging world about their latest research into imaging technique
• See imaging techniques you know being used for procedures you do not know
• Learn where the future lies for imaging in oncology
• Network with the people you need to know in the imaging arena
>>>
PLUS
a pre conference workshop in association with
3D Metrics
<<<
Differentiating Cell Types as a Precondition for Diagnosing and Treating Cancer
Hosted by Sabine McNeill, Director,3D-Metrics
9th March 2010, Crowne Plaza Hotel – St James, London
This workshop will cover an innovative approach to image analysis, which allows for comparing images as a whole as well as regions of interest. This means that hundreds and thousands of images can be compared at 'pixel resolution', which means at more detail and with more accuracy than the imaging technology currently used. Existing images are 're-visualised' on an individual basis for the human eye. Development is taking place so that hundreds and thousands of images can be 'viewed' by the software in an automated fashion. However, this requires input from the image analysts who are familiar with what they are looking for.
HOW TO BOOK
To book please visit: www.smi-online.co.uk/2010oncology24.asp
Alternatively, Contact Daniel Davies tel: +44 (0) 20 7827 6060 or email: ddavies@smi-online.co.uk
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
